SEC Form 4 · accession 0001209191-15-072320

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President, Finance

Period of report

Sep 24, 2015

Accepted (ET)

Sep 28, 2015 · 5:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001439222

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common stock^F1	Sep 24, 2015	M	10,000	—	A	10,000	D
Common stock	Sep 24, 2015	F	4,856	$88.89	D	5,144	D
Common stock	Sep 24, 2015	M	856	$23.10	A	6,000	D
Common stock^F4	Sep 24, 2015	S	6,000	$85.97	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted stock units^F1,F5	—	Sep 24, 2015	M	10,000	D	—	—	Common stock	10,000	0	D
Stock option (right to buy)^F6	$23.10	Sep 24, 2015	M	856	D	—	Aug 27, 2023	Common stock	856	88,242	D

F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $85.09 to $87.70. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5The restricted stock units were granted on September 24, 2014 and vested in full on September 24, 2015.
F6This option was granted on August 28, 2013. The shares underlying this option vest as to 25% of the underlying shares on August 28, 2014, with the remaining 75% vesting in 36 equal monthly installments thereafter.